Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
---|---|---|---|---|---|---|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) | BioMarin Pharmaceutical Inc. | Completed | BMN 110 | 3 | MOR-004 | King Faisal Specialist Hospital and Research Center (Riyadh) |
Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy | Roche | Completed | Tocilzumab | 3b | MA21573 | King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz University Hospital (Jeddah) |
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine. | Pfizer | Completed | 13-valent Pneumoccocal Conjugate Vaccine | 3 | B1851013 | King Faisal Specialist Hospital and Research Center (Riyadh) |